Comparison of risk stratification of ER-positive, node-negative breast cancer patients by Oncotype DX versus molecular grade index and HOXB13/IL17BR ratio

被引：0

|

作者：

Sgroi, D.

Hameed, O.

Hattab, E.

Chang, B.

Moulis, S.

Steffel, L.

Salunga, R.

Ma, X.

Erlander, M.

Goss, P.

机构：

[1] Harvard Univ, Sch Med, Massachussets Gen Hosp, Charlestown, MA USA

[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA

[3] Indiana Univ, Indianapolis, IN 46204 USA

[4] Scripps Mem Hosp, La Jolla, CA USA

[5] AviaraDx, San Diego, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.22061

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

22061

引用

收藏

页数：1

相关论文

共 43 条

[41] Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in African American (AA) and Caucasian (C) patients with hormone receptor-positive (HR+), HER2-negative (HER2-), lymph node-negative (LNN) breast cancer (BC)
Kabaker, K. B.
Canar, J.
Rao, R. D.
Cobleigh, M. A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[42] Using the 21-gene recurrence score and the recently developed Recurrence Score-Clinical-Pathologic to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.
Crager, M.
Tang, G.
Shak, S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[43] Molecular Classification with 21 Gene Assay (Oncotype DX) Shows in 196,967 ER Positive Patients High Frequency of Low Recurrence Score [LRS] in Both Node Positive (Ni-) and Negative (N-) Breast Cancer (BrCa) Cohorts. Definition of Chemoresistance Based on LRS with Cost and Guideline Implications.
Ragaz, J.
Wilson, K. S.
Wong, H.
Muraca, G.
Hryniuk, W.
Bajdik, C.
CANCER RESEARCH, 2011, 71

← 1 2 3 4 5 →